1 – 32 of 32
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Antibodies targeting the shared cytokine receptor IL-1 receptor accessory protein invoke distinct mechanisms to block all cytokine signaling
2024) In Cell Reports(
- Contribution to journal › Article
- 2023
-
Mark
The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
(
- Contribution to journal › Article
-
Mark
Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity
(
- Contribution to journal › Article
- 2022
-
Mark
Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations
(
- Contribution to journal › Letter
- 2021
-
Mark
Combinatorial molecule screening identifies a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
(
- Contribution to journal › Article
-
Mark
Single-cell sequencing in translational cancer research and challenges to meet clinical diagnostic needs
(
- Contribution to journal › Scientific review
- 2020
-
Mark
13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking
(
- Contribution to journal › Article
-
Mark
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells
(
- Contribution to journal › Article
-
Mark
Clonal competition within complex evolutionary hierarchies shapes AML over time
(
- Contribution to journal › Article
- 2019
-
Mark
Arrayed molecular barcoding identifies TNFSF13 as a positive regulator of acute myeloid leukemia-initiating cells
(
- Contribution to journal › Article
-
Mark
PAX5 is part of a functional transcription factor network targeted in lymphoid leukemia
(
- Contribution to journal › Article
- 2018
-
Mark
CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting
(
- Contribution to journal › Article
-
Mark
Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner
(
- Contribution to journal › Article
- 2017
-
Mark
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells
(
- Contribution to journal › Article
-
Mark
Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS and neurological symptoms
(
- Contribution to journal › Article
- 2016
-
Mark
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy
(
- Contribution to journal › Article
-
Mark
Clonal conversion of B lymphoid leukemia reveals cross-lineage transfer of malignant states
(
- Contribution to journal › Article
-
Mark
IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models
(
- Contribution to journal › Article
- 2015
-
Mark
IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.
(
- Contribution to journal › Article
-
Mark
Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
(
- Contribution to journal › Article
-
Mark
Ebf1 heterozygosity results in increased DNA damage in pro-B cells and their synergistic transformation by Pax5 haploinsufficiency.
(
- Contribution to journal › Article
- 2014
-
Mark
Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells.
(
- Contribution to journal › Article
-
Mark
RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.
(
- Contribution to journal › Letter
- 2013
-
Mark
SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.
(
- Contribution to journal › Article
-
Mark
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
(
- Contribution to journal › Article
-
Mark
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.
(
- Contribution to journal › Article
- 2011
-
Mark
SMAD4 binds HOXA9 in the cytoplasm and protects primitive hematopoietic cells against nuclear activation by HOXA9 and leukemia transformation.
(
- Contribution to journal › Article
- 2010
-
Mark
The Proportion of Ph+CD34(+)CD38(neg) Leukemic Stem Cells In the Bone Marrow of Newly Diagnosed Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Is Variable and Correlates with High Sokal Risk, High Leukocyte Count, Low Hemoglobin Concentration, Splenomegaly and Increased Hematological Toxicity During Initial TKI Therapy Data From a Randomized Phase II NordCML006 Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice
(
- Contribution to journal › Article
-
Mark
SMAD4 Sequestrates HOXA9 to Protect Hematopoietic Stem Cells Against Leukemia Transformation
(
- Contribution to journal › Published meeting abstract
-
Mark
Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells.
(
- Contribution to journal › Article
-
Mark
Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.
(
- Contribution to journal › Article